| scholarly article | Q13442814 |
| P2093 | author name string | Dineo Khabele | |
| P2860 | cites work | Functional domains of histone deacetylase-3 | Q77457202 |
| Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination | Q84718317 | ||
| Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr | Q87259669 | ||
| HDAC2 regulates chromatin plasticity and enhances DNA vulnerability | Q24316879 | ||
| The many roles of histone deacetylases in development and physiology: implications for disease and therapy | Q24628821 | ||
| HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination | Q24670026 | ||
| Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex | Q24682541 | ||
| Neutralizing tumor-promoting chronic inflammation: a magic bullet? | Q26830931 | ||
| New and emerging HDAC inhibitors for cancer treatment | Q27022413 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Duration of nuclear NF-kappaB action regulated by reversible acetylation | Q28215080 | ||
| A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p | Q28276243 | ||
| Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function | Q28283633 | ||
| Acetylation of non-histone proteins modulates cellular signalling at multiple levels | Q28294575 | ||
| Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma | Q28534761 | ||
| The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3 | Q28609763 | ||
| Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia | Q29616211 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Acetylation and deacetylation of non-histone proteins | Q29619636 | ||
| A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q30445663 | ||
| Chemical phylogenetics of histone deacetylases | Q30977637 | ||
| Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression | Q33276186 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma | Q33394324 | ||
| A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q33399902 | ||
| Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer | Q33405711 | ||
| The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21 | Q33719525 | ||
| Cisplatin: from DNA damage to cancer chemotherapy. | Q34348474 | ||
| Cancer of the ovary | Q34375262 | ||
| Hdac3 is essential for the maintenance of chromatin structure and genome stability | Q34417264 | ||
| Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype | Q34508811 | ||
| Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer | Q34582674 | ||
| Histone deacetylase inhibitors as anti-neoplastic agents. | Q34974183 | ||
| Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer | Q35032491 | ||
| Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents | Q35051134 | ||
| Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm | Q35140600 | ||
| Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer | Q35141937 | ||
| Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. | Q35476003 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. | Q39867142 | ||
| Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells | Q39875544 | ||
| Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs | Q40024217 | ||
| Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis | Q40109430 | ||
| Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation | Q40117454 | ||
| Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice | Q40118539 | ||
| Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer | Q40200801 | ||
| Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo | Q40274832 | ||
| Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. | Q40349497 | ||
| Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. | Q40400391 | ||
| Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer | Q42492006 | ||
| Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. | Q42829702 | ||
| Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression | Q42951900 | ||
| FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases | Q44123685 | ||
| Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. | Q44203773 | ||
| Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. | Q44959677 | ||
| Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. | Q47860803 | ||
| Cisplatin-induced post-translational modification of histones H3 and H4. | Q47977007 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. | Q53563335 | ||
| Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA | Q53650118 | ||
| A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. | Q54270777 | ||
| Update of the NCCN ovarian cancer practice guidelines | Q74045425 | ||
| The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells | Q35556954 | ||
| Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. | Q35624730 | ||
| Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. | Q35628323 | ||
| A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment | Q35656974 | ||
| Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy | Q36088241 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| Nuclear factor-κB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. | Q36212855 | ||
| Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages | Q36342694 | ||
| Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer | Q36521908 | ||
| Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks | Q36570690 | ||
| Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control | Q36639688 | ||
| The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-κB. | Q36668758 | ||
| "Re-educating" tumor-associated macrophages by targeting NF-kappaB. | Q36699735 | ||
| Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells | Q36700778 | ||
| Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas | Q36840303 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| HDAC4 promotes growth of colon cancer cells via repression of p21. | Q36914284 | ||
| HDAC3 is essential for DNA replication in hematopoietic progenitor cells. | Q36966883 | ||
| Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype | Q36999077 | ||
| HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses | Q37073624 | ||
| HDACs and HDAC inhibitors in colon cancer | Q37104507 | ||
| Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo | Q37123516 | ||
| A work in progress: the clinical development of histone deacetylase inhibitors | Q37167166 | ||
| Histone deacetylase inhibitors and genomic instability | Q37219202 | ||
| Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer | Q37314520 | ||
| Beyond chemotherapy: targeted therapies in ovarian cancer | Q37399899 | ||
| Enhancing the apoptotic and therapeutic effects of HDAC inhibitors | Q37440094 | ||
| Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. | Q37579567 | ||
| Targeting class I histone deacetylases in cancer therapy | Q38051736 | ||
| Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma | Q38320607 | ||
| Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma | Q39336768 | ||
| Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. | Q39502973 | ||
| Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. | Q39576827 | ||
| Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage | Q39705077 | ||
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 111 | |
| P577 | publication date | 2014-05-20 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer | |
| P478 | volume | 4 |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q90328022 | Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps? |
| Q38720601 | Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells |
| Q42378478 | Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells |
| Q92324516 | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| Q59789255 | HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer |
| Q42338747 | HDAC/IKK inhibition therapies in solid tumors |
| Q38975491 | Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells |
| Q35744910 | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| Q35006481 | Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells |
| Q64280891 | PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors |
| Q38756596 | Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib |
| Q53416230 | Quantitative phosphoproteomic analysis reveals γ-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation. |
| Q33598464 | Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells |
| Q55485574 | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. |
| Q92918274 | The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer |
| Q26825361 | Transcriptional regulation of chemokine expression in ovarian cancer |
Search more.